Search

Your search keyword '"Weiss, Glen J."' showing total 607 results
Start Over Author "Weiss, Glen J."
607 results on '"Weiss, Glen J."'

1. Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model

Author

Ferrer-Lores, Blanca, Ortiz-Algarra, Alfonso, Picó-Peris, Alfonso, Estepa-Fernández, Alejandra, Bellvís-Bataller, Fuensanta, Weiss, Glen J., Fuster-Matanzo, Almudena, Fernández, Juan Pedro, Jimenez-Pastor, Ana, Hernani, Rafael, Saus-Carreres, Ana, Benzaquen, Ana, Ventura, Laura, Piñana, José Luis, Teruel, Ana Belén, Serrano-Alcalá, Alicia, Dosdá, Rosa, Sopena-Novales, Pablo, Balaguer-Rosello, Aitana, Guerreiro, Manuel, Sanz, Jaime, Martí-Bonmatí, Luis, Terol, María José, and Alberich-Bayarri, Ángel

Published
2024
Full Text
View/download PDF

2. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Author

Gettinger, Scott N, Huber, Rudolf M, Kim, Dong-Wan, Bazhenova, Lyudmila, Hansen, Karin Holmskov, Tiseo, Marcello, Langer, Corey J, Rodríguez, Luis G Paz-Ares, West, Howard L, Reckamp, Karen L, Weiss, Glen J, Smit, Egbert F, Hochmair, Maximilian J, Kim, Sang-We, Ahn, Myung-Ju, Kim, Edward S, Groen, Harry JM, Pye, Joanna, Liu, Yuyin, Zhang, Pingkuan, Vranceanu, Florin, and Camidge, D Ross

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, ALK tyrosine kinase inhibitor, Anaplastic lymphoma kinase, Brigatinib, Crizotinib, Non–small-cell lung cancer
Abstract

IntroductionWe report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK-rearrangement positive (ALK+) NSCLC.MethodsThe phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced malignancies. ALTA randomized patients with crizotinib-refractory ALK+ NSCLC to brigatinib 90 mg once daily (arm A) or 180 mg once daily (7-d lead-in at 90 mg; arm B).ResultsIn the phase 1/2 study, 79 of 137 brigatinib-treated patients had ALK+ NSCLC; 71 were crizotinib pretreated. ALTA randomized 222 patients (n = 112 in arm A; n = 110 in arm B). Median follow-up at phase 1/2 study end (≈5.6 y after last patient enrolled) was 27.7 months; at ALTA study end (≈4.4 y after last patient enrolled), 19.6 months (A) and 28.3 months (B). Among patients with ALK+ NSCLC in the phase 1/2 study, median investigator-assessed progression-free survival (PFS) was 14.5 months (95% confidence interval [CI]: 10.8-21.2); median overall survival was 47.6 months (28.6-not reached). In ALTA, median investigator-assessed PFS was 9.2 months (7.4-11.1) in arm A and 15.6 months (11.1-18.5) in arm B; median independent review committee (IRC)-assessed PFS was 9.9 (7.4-12.8) and 16.7 (11.6-21.4) months, respectively; median overall survival was 25.9 (18.2-45.8) and 40.6 (32.5-not reached) months, respectively. Median intracranial PFS for patients with any brain metastases was 12.8 (9.2-18.4) months in arm A and 18.4 (12.6-23.9) months in arm B. No new safety signals were identified versus previous analyses.ConclusionsBrigatinib exhibited sustained long-term activity and PFS with manageable safety in patients with crizotinib-refractory ALK+ NSCLC.

Published
2022

3. Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions

Author

Seelbinder, Bastian, Lohinai, Zoltan, Vazquez-Uribe, Ruben, Brunke, Sascha, Chen, Xiuqiang, Mirhakkak, Mohammad, Lopez-Escalera, Silvia, Dome, Balazs, Megyesfalvi, Zsolt, Berta, Judit, Galffy, Gabriella, Dulka, Edit, Wellejus, Anja, Weiss, Glen J., Bauer, Michael, Hube, Bernhard, Sommer, Morten O. A., and Panagiotou, Gianni

Published
2023
Full Text
View/download PDF

14. Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status

Author

Dora, David, primary, Ligeti, Balazs, additional, Kovacs, Tamas, additional, Revisnyei, Peter, additional, Galffy, Gabriella, additional, Dulka, Edit, additional, Krizsán, Dániel, additional, Kalcsevszki, Regina, additional, Megyesfalvi, Zsolt, additional, Dome, Balazs, additional, Weiss, Glen J., additional, and Lohinai, Zoltan, additional

Published
2023
Full Text
View/download PDF

16. Supplementary Tables from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Author

Tabernero, Josep, primary, Shapiro, Geoffrey I., primary, LoRusso, Patricia M., primary, Cervantes, Andres, primary, Schwartz, Gary K., primary, Weiss, Glen J., primary, Paz-Ares, Luis, primary, Cho, Daniel C., primary, Infante, Jeffrey R., primary, Alsina, Maria, primary, Gounder, Mrinal M., primary, Falzone, Rick, primary, Harrop, Jamie, primary, White, Amy C. Seila, primary, Toudjarska, Iva, primary, Bumcrot, David, primary, Meyers, Rachel E., primary, Hinkle, Gregory, primary, Svrzikapa, Nenad, primary, Hutabarat, Renta M., primary, Clausen, Valerie A., primary, Cehelsky, Jeffrey, primary, Nochur, Saraswathy V., primary, Gamba-Vitalo, Christina, primary, Vaishnaw, Akshay K., primary, Sah, Dinah W.Y., primary, Gollob, Jared A., primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figures from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Author

Tabernero, Josep, primary, Shapiro, Geoffrey I., primary, LoRusso, Patricia M., primary, Cervantes, Andres, primary, Schwartz, Gary K., primary, Weiss, Glen J., primary, Paz-Ares, Luis, primary, Cho, Daniel C., primary, Infante, Jeffrey R., primary, Alsina, Maria, primary, Gounder, Mrinal M., primary, Falzone, Rick, primary, Harrop, Jamie, primary, White, Amy C. Seila, primary, Toudjarska, Iva, primary, Bumcrot, David, primary, Meyers, Rachel E., primary, Hinkle, Gregory, primary, Svrzikapa, Nenad, primary, Hutabarat, Renta M., primary, Clausen, Valerie A., primary, Cehelsky, Jeffrey, primary, Nochur, Saraswathy V., primary, Gamba-Vitalo, Christina, primary, Vaishnaw, Akshay K., primary, Sah, Dinah W.Y., primary, Gollob, Jared A., primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

23. Data from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Author

Tabernero, Josep, primary, Shapiro, Geoffrey I., primary, LoRusso, Patricia M., primary, Cervantes, Andres, primary, Schwartz, Gary K., primary, Weiss, Glen J., primary, Paz-Ares, Luis, primary, Cho, Daniel C., primary, Infante, Jeffrey R., primary, Alsina, Maria, primary, Gounder, Mrinal M., primary, Falzone, Rick, primary, Harrop, Jamie, primary, White, Amy C. Seila, primary, Toudjarska, Iva, primary, Bumcrot, David, primary, Meyers, Rachel E., primary, Hinkle, Gregory, primary, Svrzikapa, Nenad, primary, Hutabarat, Renta M., primary, Clausen, Valerie A., primary, Cehelsky, Jeffrey, primary, Nochur, Saraswathy V., primary, Gamba-Vitalo, Christina, primary, Vaishnaw, Akshay K., primary, Sah, Dinah W.Y., primary, Gollob, Jared A., primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Methods and Legends from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Author

Tabernero, Josep, primary, Shapiro, Geoffrey I., primary, LoRusso, Patricia M., primary, Cervantes, Andres, primary, Schwartz, Gary K., primary, Weiss, Glen J., primary, Paz-Ares, Luis, primary, Cho, Daniel C., primary, Infante, Jeffrey R., primary, Alsina, Maria, primary, Gounder, Mrinal M., primary, Falzone, Rick, primary, Harrop, Jamie, primary, White, Amy C. Seila, primary, Toudjarska, Iva, primary, Bumcrot, David, primary, Meyers, Rachel E., primary, Hinkle, Gregory, primary, Svrzikapa, Nenad, primary, Hutabarat, Renta M., primary, Clausen, Valerie A., primary, Cehelsky, Jeffrey, primary, Nochur, Saraswathy V., primary, Gamba-Vitalo, Christina, primary, Vaishnaw, Akshay K., primary, Sah, Dinah W.Y., primary, Gollob, Jared A., primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

29. Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung Cancer.

Author

Dora, David, Weiss, Glen J., Megyesfalvi, Zsolt, Gállfy, Gabriella, Dulka, Edit, Kerpel-Fronius, Anna, Berta, Judit, Moldvay, Judit, Dome, Balazs, and Lohinai, Zoltan

Subjects
*LUNG cancer, *IMMUNE checkpoint inhibitors, *ENTEROCOCCUS faecium, *GUT microbiome, *BACTEROIDES, *ARTIFICIAL intelligence, *MACHINE learning, *GENE expression, *RESEARCH funding, *GENOMICS, *DESCRIPTIVE statistics, *COMPUTED tomography, *PREDICTION models, *CLOSTRIDIUM, *OVERALL survival
Abstract

Simple Summary: There is a lack of understanding of the pathogenesis and mechanisms accounting for the large variability in tumor response to immune checkpoint inhibition. In this study, we investigate the role and composition of the human gut microbiome in the clinical setting by integrating shotgun metagenomics and quantitative texture analysis (QTA) of CT images in NSCLC patients treated with anti-PD-L1 immunotherapy using a novel machine learning approach. Using all available parameters, the XGB machine learning system predicted therapeutic response with an accuracy of 83% and correctly separated long-term survival patients from short-term survival patients with an accuracy of 69%. Our findings show that an integrated signature of these characteristics may predict outcomes more accurately than separate measures and may have potential therapeutic implications in the future. This study aims to combine computed tomography (CT)-based texture analysis (QTA) and a microbiome-based biomarker signature to predict the overall survival (OS) of immune checkpoint inhibitor (ICI)-treated non-small cell lung cancer (NSCLC) patients by analyzing their CT scans (n = 129) and fecal microbiome (n = 58). One hundred and five continuous CT parameters were obtained, where principal component analysis (PCA) identified seven major components that explained 80% of the data variation. Shotgun metagenomics (MG) and ITS analysis were performed to reveal the abundance of bacterial and fungal species. The relative abundance of Bacteroides dorei and Parabacteroides distasonis was associated with long OS (>6 mo), whereas the bacteria Clostridium perfringens and Enterococcus faecium and the fungal taxa Cortinarius davemallochii, Helotiales, Chaetosphaeriales, and Tremellomycetes were associated with short OS (≤6 mo). Hymenoscyphus immutabilis and Clavulinopsis fusiformis were more abundant in patients with high (≥50%) PD-L1-expressing tumors, whereas Thelephoraceae and Lachnospiraceae bacterium were enriched in patients with ICI-related toxicities. An artificial intelligence (AI) approach based on extreme gradient boosting evaluated the associations between the outcomes and various clinicopathological parameters. AI identified MG signatures for patients with a favorable ICI response and high PD-L1 expression, with 84% and 79% accuracy, respectively. The combination of QTA parameters and MG had a positive predictive value of 90% for both therapeutic response and OS. According to our hypothesis, the QTA parameters and gut microbiome signatures can predict OS, the response to therapy, the PD-L1 expression, and toxicity in NSCLC patients treated with ICI, and a machine learning approach can combine these variables to create a reliable predictive model, as we suggest in this research. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Supplementary Fig. S1. Total Soluble SEMA4D Levels as a Function of Weekly VX15/2503 Administration from Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

Author

Patnaik, Amita, primary, Weiss, Glen J., primary, Leonard, John E., primary, Rasco, Drew Warren, primary, Sachdev, Jasgit C., primary, Fisher, Terrence L., primary, Winter, Laurie A., primary, Reilly, Christine, primary, Parker, Robert B., primary, Mutz, Danielle, primary, Blaydorn, Lisa, primary, Tolcher, Anthony W., primary, Zauderer, Maurice, primary, and Ramanathan, Ramesh K., primary

Published
2023
Full Text
View/download PDF

31. Data from Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Author

Weiss, Glen J., primary, Infante, Jeffrey R., primary, Chiorean, E. Gabriela, primary, Borad, Mitesh J., primary, Bendell, Johanna C., primary, Molina, Julian R., primary, Tibes, Raoul, primary, Ramanathan, Ramesh K., primary, Lewandowski, Karen, primary, Jones, Suzanne F., primary, Lacouture, Mario E., primary, Langmuir, Virginia K., primary, Lee, Hank, primary, Kroll, Stew, primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure Legend from Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

Author

Patnaik, Amita, primary, Weiss, Glen J., primary, Leonard, John E., primary, Rasco, Drew Warren, primary, Sachdev, Jasgit C., primary, Fisher, Terrence L., primary, Winter, Laurie A., primary, Reilly, Christine, primary, Parker, Robert B., primary, Mutz, Danielle, primary, Blaydorn, Lisa, primary, Tolcher, Anthony W., primary, Zauderer, Maurice, primary, and Ramanathan, Ramesh K., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Tables 1-3 from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure S1 from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table 3 from Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy

Author

Weiss, Glen J., primary, Beck, Julia, primary, Braun, Donald P., primary, Bornemann-Kolatzki, Kristen, primary, Barilla, Heather, primary, Cubello, Rhiannon, primary, Quan, Walter, primary, Sangal, Ashish, primary, Khemka, Vivek, primary, Waypa, Jordan, primary, Mitchell, William M., primary, Urnovitz, Howard, primary, and Schütz, Ekkehard, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure Legend from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figures S1-S2 from Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Author

Weiss, Glen J., primary, Infante, Jeffrey R., primary, Chiorean, E. Gabriela, primary, Borad, Mitesh J., primary, Bendell, Johanna C., primary, Molina, Julian R., primary, Tibes, Raoul, primary, Ramanathan, Ramesh K., primary, Lewandowski, Karen, primary, Jones, Suzanne F., primary, Lacouture, Mario E., primary, Langmuir, Virginia K., primary, Lee, Hank, primary, Kroll, Stew, primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

38. Supplemental Section - Clean from Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Author

Von Hoff, Daniel D., primary, Mita, Monica M., primary, Ramanathan, Ramesh K., primary, Weiss, Glen J., primary, Mita, Alain C., primary, LoRusso, Patricia M., primary, Burris, Howard A., primary, Hart, Lowell L., primary, Low, Susan C., primary, Parsons, Donald M., primary, Zale, Stephen E., primary, Summa, Jason M., primary, Youssoufian, Hagop, primary, and Sachdev, Jasgit C., primary

Published
2023
Full Text
View/download PDF

39. Data from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Methods from Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

Author

Patnaik, Amita, primary, Weiss, Glen J., primary, Leonard, John E., primary, Rasco, Drew Warren, primary, Sachdev, Jasgit C., primary, Fisher, Terrence L., primary, Winter, Laurie A., primary, Reilly, Christine, primary, Parker, Robert B., primary, Mutz, Danielle, primary, Blaydorn, Lisa, primary, Tolcher, Anthony W., primary, Zauderer, Maurice, primary, and Ramanathan, Ramesh K., primary

Published
2023
Full Text
View/download PDF

41. Supplemental Figure 1 from Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Author

Sarantopoulos, John, primary, Shapiro, Geoffrey I., primary, Cohen, Roger B., primary, Clark, Jeffrey W., primary, Kauh, John S., primary, Weiss, Glen J., primary, Cleary, James M., primary, Mahalingam, Devalingam, primary, Pickard, Michael D., primary, Faessel, Hélène M., primary, Berger, Allison J., primary, Burke, Kristine, primary, Mulligan, George, primary, Dezube, Bruce J., primary, and Harvey, R. Donald, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data from First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Author

Papadopoulos, Kyriakos P., primary, Johnson, Melissa L., primary, Lockhart, Albert C., primary, Moore, Kathleen, primary, Falchook, Gerald S., primary, Formenti, Silvia C., primary, Naing, Aung, primary, Carvajal, Richard D., primary, Rosen, Lee S., primary, Weiss, Glen J., primary, Leidner, Rom S., primary, Li, Jingjin, primary, Paccaly, Anne, primary, Feng, Minjie, primary, Stankevich, Elizabeth, primary, Lowy, Israel, primary, Fury, Matthew G., primary, and Crittenden, Marka R., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Data from Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Tibes, Raoul, primary, Gordon, Michael S., primary, Wong, Bryan Y., primary, Eder, Joseph Paul, primary, Borad, Mitesh J., primary, Mendelson, David S., primary, Vogelzang, Nicholas J., primary, Bastos, Bruno R., primary, Weiss, Glen J., primary, Fernandez, Cristian, primary, Sutherland, William, primary, Sato, Hitoshi, primary, Pierceall, William E., primary, Weaver, David, primary, Slough, Scott, primary, Wasserman, Ernesto, primary, Kufe, Donald W., primary, Von Hoff, Daniel, primary, Kawabe, Takumi, primary, and Sharma, Sunil, primary

Published
2023
Full Text
View/download PDF

44. Related CCR Translation from Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

Author

LoRusso, Patricia M., primary, Rudin, Charles M., primary, Reddy, Josina C., primary, Tibes, Raoul, primary, Weiss, Glen J., primary, Borad, Mitesh J., primary, Hann, Christine L., primary, Brahmer, Julie R., primary, Chang, Ilsung, primary, Darbonne, Walter C., primary, Graham, Richard A., primary, Zerivitz, Kenn L., primary, Low, Jennifer A., primary, and Von Hoff, Daniel D., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Tables, Supplementary Figure Legend and Supplementary Figures from Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy

Author

Weiss, Glen J., primary, Beck, Julia, primary, Braun, Donald P., primary, Bornemann-Kolatzki, Kristen, primary, Barilla, Heather, primary, Cubello, Rhiannon, primary, Quan, Walter, primary, Sangal, Ashish, primary, Khemka, Vivek, primary, Waypa, Jordan, primary, Mitchell, William M., primary, Urnovitz, Howard, primary, and Schütz, Ekkehard, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Tables 1-2, Supplementary Methods, Supplementary Figure Legend from Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Author

Sarantopoulos, John, primary, Shapiro, Geoffrey I., primary, Cohen, Roger B., primary, Clark, Jeffrey W., primary, Kauh, John S., primary, Weiss, Glen J., primary, Cleary, James M., primary, Mahalingam, Devalingam, primary, Pickard, Michael D., primary, Faessel, Hélène M., primary, Berger, Allison J., primary, Burke, Kristine, primary, Mulligan, George, primary, Dezube, Bruce J., primary, and Harvey, R. Donald, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results